Non‐surgical treatment of hepatocarcinoma

Hepatocellular carcinoma (HCC) is one of the most common tumors affecting man. It is the general feeling that only hepatectomy can give a chance for cure. However, less than 20% of patients can be resected, and other treatment modalities are required. Systemic (chemotherapy, hormonotherapy, immunotherapy) and loco‐regional (intratumoral injection of alcohol, intra‐arterial chemotherapy embolization, internal radiotherapy) approaches have been developed. In view of the small number of patients, tumor and patient heterogeneity, and difficulties in assessing tumor response, the real place of these treatments is difficult to evaluate. A review of the literature suggests that embolization with Gelfoam, even when given without chemotherapy, has an effect on response rate and on survival, and could be considered, at the present time, as the most attractive treatment in non‐operable HCC. Chemotherapy seems effective only if combined with embolization. When administered alone by the systemic or the intra‐arterial hepatic route, no clinically significant activity can be found. Unexpectedly, Lipiodol by itself seems inactive, and the co‐administration of chemotherapy does not improve activity. Other approaches such as intratumoral injection of alcohol, immunotherapy, hormonotherapy, and radioimmunotherapy are still experimental, and well‐designed studies are needed to identify their role. © 1993 Wiley‐Liss, Inc. Copyright © 1993 Wiley‐Liss, Inc. A Wiley CompanySCOPUS: ar.jFLWNAinfo:eu-repo/semantics/publishe

Transjugular intrahepatic postosystemic stent-shunt in myeloid metaplasia

SCOPUS: le.jFLWNAinfo:eu-repo/semantics/publishe

CA-125 in primary mediastinal B-cell lymphoma with sclerosis [1]

SCOPUS: le.jinfo:eu-repo/semantics/publishe

Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40-CD40L interactions with T helper cells

Immune mechanisms have been shown to contribute to the process of myelodysplastic syndromes (MDS)-related bone marrow (BM) failure. The aim of this study was to evaluate the possible contribution of activated monocytes through CD40-CD40L(CD154) interactions with activated T helper cells. We demonstrated in 77 predominantly lower risk MDS patients that the CD40 receptor was expressed significantly higher on monocytes and that CD40L was expressed significantly higher on T helper cells in peripheral blood (PB) and BM. Increased levels of CD40 and CD40L were detected in the same patients. In addition, stimulation of the CD40 receptor on purified PB monocytes led to a significantly higher tumor necrosis factor alpha production in patients. Co-culture of BM mononuclear cells of 21 patients in the presence of a blocking CD40 monoclonal antibody (ch5D12) led to a significant increase in the number of colony-forming units. A correlation was seen between increased CD40 expression on monocytes with patients' age below 60 years and with the cytogenetic abnormality trisomy 8. These results demonstrate that CD40 expression on monocytes may identify a subgroup of MDS patients in whom immune-mediated hematopoietic failure is part of the disease process. As such, the CD40-CD40L-based activation of monocytes might be a target to counteract MDS-related BM failure.status: publishe

Tumour stimulating effects of recombinant human interleukin-6.

Clinical TrialClinical Trial, Phase ILetterinfo:eu-repo/semantics/publishe

Mediastinal diffuse large cell lymphoma with sclerosis: evidence for clonal immunoglobulin gene rearrangements

info:eu-repo/semantics/publishe

Optimal blood stem cell mobilization using 10 μg/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: An intrapatient controlled study

SCOPUS: ar.jFLWNAinfo:eu-repo/semantics/publishe

Phase II trial with hormono-chemotherapy combining high-dose tamoxifen (HD-TAM), cisplatin (DDP) and fotemustine in metastasic malignant melanoma (MMM): Pilot study evaluation

0info:eu-repo/semantics/publishe